GSK, Sanofi Score Another $2.1 Billion for COVID-19 Vaccine Development, an Industrial Info Market Brief
GSK, Sanofi Score Another $2.1 Billion for COVID-19 Vaccine Development, an Industrial Info Market Brief
Attachment: COVID US vax 0820
The U.S. Department of Health and Human Services' "Operation Warp Speed" is sending an additional $2.1 billion to GlaxoSmithKline (GSK) and Sanofi to speed up the development of a recombinant protein-based vaccine for COVID-19.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
